Journal of Neuro-Oncology

, Volume 81, Issue 2, pp 175–184 | Cite as

Cognitive functions in low-grade gliomas: disease and treatment effects

  • Denise D. CorreaEmail author
  • Lisa M. DeAngelis
  • Weiji Shi
  • Howard T. Thaler
  • Michael Lin
  • Lauren E. Abrey



The role of radiotherapy and chemotherapy in the treatment of low-grade gliomas (LGG) is controversial regarding their effect on survival and the development of neurotoxicity. The few published studies examining adverse treatment effects on cognition revealed conflicting results.


To assess cognitive functioning in LGG patients who received conformal radiation therapy (RT), chemotherapy, or no treatment.


40 LGG patients participated in the study; 16 patients had RT ± chemotherapy, and 24 patients had no treatment. All patients underwent a neuropsychological evaluation. APOE genotype was obtained in 36 patients who were classified in two groups based on the presence or absence of at least one apolipoprotein E є-4 (APOE є-4) allele.


Treated LGG patients had lower scores than untreated patients on several cognitive domains; patients who completed treatment at intervals greater than 3 years and had long disease duration had significantly lower scores on the Non-Verbal Memory domain. Antiepileptic polytherapy, treatment history, and disease duration jointly contributed to low Psychomotor domain scores. 62% of treated patients showed white matter confluence on MRI, whereas only 9% of the untreated patients had such changes. Preliminary comparisons between APOE є-4 carriers (n = 9) and non-carriers (n = 27) on cognitive domain scores revealed no statistically significant differences, but APOE є-4 carriers had lower mean scores on the Verbal Memory domain than did non-є-4 carriers.


RT ± chemotherapy, disease duration, and antiepileptic treatment contributed to mild cognitive difficulties in LGG patients.


Low-grade glioma Radiation Chemotherapy Neuropsychology Cognitive 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.



The authors thank Aviva Glass, Angeles Cheung, and Jocelyn Dantis for their assistance with data acquisition and management.


  1. 1.
    Guthrie BL, Laws ER Jr (1990) Supratentorial low-grade gliomas. Neurosurg Clin N Am 1:37–48PubMedGoogle Scholar
  2. 2.
    Davis FG, Freels S, Grutsch J, Barlas S, Brem S (1998) Survival rates in patients with primary malignant brain tumors stratified by age and tumor histological type: an analysis based on surveillance, epidemiology, and end results (SEER) data, 1973–1991. J Neurosurg 88:1–10PubMedCrossRefGoogle Scholar
  3. 3.
    Olson JD, Riedel E, DeAngelis LM (2000) Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 54:1442–1448PubMedGoogle Scholar
  4. 4.
    Levin VA (1996) Controversies in the treatment of low-grade astrocytomas and oligodendrogliomas. Curr Opin Oncol 8:175–177PubMedGoogle Scholar
  5. 5.
    Lunsford LD, Kondziolka D (2001) Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology 57:2150–2151PubMedGoogle Scholar
  6. 6.
    Buckner JC, Gesme D Jr, O’Fallon JR et al (2003) Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 21:251–255PubMedCrossRefGoogle Scholar
  7. 7.
    Stieber VW (2001) Low-grade gliomas. Curr Treat Options Oncol 2:495–506PubMedGoogle Scholar
  8. 8.
    Shaw EG (1995) The low-grade glioma debate: evidence defending the position of early radiotherapy. Clin Neur 42:448–494Google Scholar
  9. 9.
    Shaw EG, Tatter SB, Lesser GJ et al (2004) Current controversies in the radiotherapeutic management of adult low-grade glioma. Semin Oncol 31:653–658PubMedCrossRefGoogle Scholar
  10. 10.
    Lindegaard KF, Mork SJ, Eide GE et al (1987) Statistical analysis of clinicopathological features, radiotherapy, and survival in 170 cases of oligodendroglioma. J Neurosurg 67:224–230PubMedCrossRefGoogle Scholar
  11. 11.
    Karim AB, Afra D, Cornu P et al (2002) Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer study 22845 with the Medical Research Council study BR04: an interim analysis. Int J Radiat Oncol 52:316–324CrossRefGoogle Scholar
  12. 12.
    Karim AB, Maat B, Hatlevoll R et al (1996) A randomized trial on dose–response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of cancer (EORTC) Study 22844. Int J Radiat Oncol 36:549–556CrossRefGoogle Scholar
  13. 13.
    Karim AB, Cornu P, Bleehen N et al (1998) Immediate postoperative radiotherapy in low-grade glioma improves progression free survival, but not overall survival: preliminary results of an EORTC/MRC randomized phase III study. Proc Am Soc Clin Oncol 17:400AGoogle Scholar
  14. 14.
    Brown PD, Buckner JC, Uhm JH, Shaw EG (2003) The neurocognitive effects of radiation in adult low-grade glioma patients. Neuro-Oncology 5:161–167PubMedCrossRefGoogle Scholar
  15. 15.
    Taphoorn MJB, Schiphorst AK, Snoek FJ et al (1994) Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy. Ann Neurol 36:48–54PubMedCrossRefGoogle Scholar
  16. 16.
    Armstrong CL, Corn BW, Ruffer JE et al (2000) Radiotherapeutic effects on brain function: double dissociation of memory systems. Neuropsychiatry Neuropsychol Behav Neurol 13:101–111PubMedGoogle Scholar
  17. 17.
    Armstrong CL, Hunter JV, Ledakis GE et al (2002) Late cognitive and radiographic changes related to radiotherapy. Neurology 59:40–48PubMedGoogle Scholar
  18. 18.
    Postma TJ, Klein M, Verstappen CCP et al (2002) Radiotherapy-induced cerebral abnormalities in patients with low-grade glioma. Neurology 59:121–123PubMedGoogle Scholar
  19. 19.
    Surma-aho O, Niemela M, Vikki J et al (2001) Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology 56:1285–1290PubMedGoogle Scholar
  20. 20.
    Vigliani MC, Sichez N, Poisson M, Delattre JY (1996) A prospective study of cognitive functions following conventional radiotherapy for supratentorial gliomas in young adults: 4-year results. Int J Radiat Oncol 35:527–533CrossRefGoogle Scholar
  21. 21.
    Pignatti F, van den Bent M, Curran D et al (2002) Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20:2076–2084PubMedCrossRefGoogle Scholar
  22. 22.
    Klein M, Engelberts NHJ, van der Ploeg HM et al (2003) Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann Neurol 54:514–520PubMedCrossRefGoogle Scholar
  23. 23.
    Ahles TA, Saykin AJ, Noll WW et al (2003) The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psycho-Oncol 12:612–619CrossRefGoogle Scholar
  24. 24.
    Richard F, Amoyel P (2001) Genetic susceptibility factors for Alzheimer’s disease. Eur J Pharmacol 412:1–12PubMedCrossRefGoogle Scholar
  25. 25.
    Nicoll JAR, Roberts GW, Graham DI (1995) Apolipoprotein E ε-4 allele is associated with deposition of amyloid ε-4-protein following head injury. Nat Med 1:135–137PubMedCrossRefGoogle Scholar
  26. 26.
    Jordan BD, Kanik AB, Horwich MS et al (1995) Apolipoprotein E ε-4 and fatal cerebral amyloid angiopathy associated with dementia pugilistica. Ann Neurol 38:698–699PubMedCrossRefGoogle Scholar
  27. 27.
    Kutner KC, Erlanger DM, Tsai J, Jordan B, Relkin N (2000) Lower cognitive performance of older football players possessing apolipoprotein E ε-4. Neurosurgery 47:651–658PubMedCrossRefGoogle Scholar
  28. 28.
    Tardiff BE, Newman MF, Saunders AM (1997) Preliminary report of a genetic basis for cognitive decline after cardiac operations. Ann Thorac Surg 64:715–720PubMedCrossRefGoogle Scholar
  29. 29.
    Lezak MD (1995) Neuropsychological assessment, 3rd edn. Oxford University Press, New YorkGoogle Scholar
  30. 30.
    Weitzner MA, Meyers CA, Gelke CK, Byrne KS, Cella DF, Levin VA (1995) The Functional Assessment of Cancer Therapy (FACT) Scale: development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 75:1151–1161PubMedCrossRefGoogle Scholar
  31. 31.
    Hixson JE, Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31:545–548PubMedGoogle Scholar
  32. 32.
    Crook R, Hardy J, Duff K (1994) Single-day apolipoprotein E genotyping. J Neurosci Meth 53:125–127CrossRefGoogle Scholar
  33. 33.
    Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA (1987) MR signal abnormalities at 1.5 T in Alzheimer’s␣dementia and normal aging. Am J Neuroradiol 8:421–426Google Scholar
  34. 34.
    Weitzner MA, Meyers CA (1997) Cognitive functioning and quality of life in malignant glioma patients: a review of the literature. Psycho-Oncol 6:169–177CrossRefGoogle Scholar
  35. 35.
    Correa DD, DeAngelis LM, Shi W et al (2004) Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 62:548–555PubMedGoogle Scholar
  36. 36.
    Klein M, Heimans JJ (2004) The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. J Clin Oncol 22:966–967PubMedCrossRefGoogle Scholar
  37. 37.
    Fjell AM, Walhovd KB, Reinvang I et al (2005) Age does not increase rate of forgetting over weeks—neuroanatomical volumes and visual memory across the adult life-span. J Int Neuropsych Soc 11:2–15CrossRefGoogle Scholar
  38. 38.
    Tulving E, Markowitsch HJ, Craik FIM et al (1996) Novelty and familiarity activations in PET studies of memory encoding and retrieval. Cereb Cortex 6:71–79PubMedGoogle Scholar
  39. 39.
    Martin A (1999) Automatic activation of the medial temporal lobe during encoding: lateralized influences of meaning and novelty. Hippocampus 9:62–70PubMedCrossRefGoogle Scholar
  40. 40.
    Goldberg E, Podell K, Lovell M (1994) Lateralization of frontal lobe functions and novelty. J Neuropsych Clin Ni 6:371–378Google Scholar
  41. 41.
    Benedict RHB, Bakshi R, Simon JH et al (2002) Frontal cortex atrophy predicts cognitive impairment in multiple sclerosis. J Neuropsychiatry Clin N 14:44–51CrossRefGoogle Scholar
  42. 42.
    Tullberg M, Fletcher E, DeCarli E et al (2004) White matter lesions impair frontal lobe function regardless of their location. Neurology 63:246–253PubMedGoogle Scholar
  43. 43.
    Aldenkamp AP (2001) Effects of antiepileptic drugs on cognition. Epilepsia 41:46–49CrossRefGoogle Scholar
  44. 44.
    Laack NN, Brown PD, Furth A et al (2003) Neurocognitive function after radiotherapy (RT) for supratentorial low-grade gliomas (LGG): results of a north central cancer treatment group (NCCTG) prospective study. Int J Radiat Oncol 57:S134CrossRefGoogle Scholar
  45. 45.
    Torres IJ, Mundt AJ, Sweeney PJ et al (2003) A longitudinal neuropsychological study of partial brain radiation in adults with brain tumors. Neurology 60:1113–1118PubMedGoogle Scholar
  46. 46.
    Bondi MW, Salmon DP, Monsch AU et al (1995) Episodic memory changes are associated with the APOE-epsilon 4 allele in nondemented older adults. Neurology 46:2203–2206Google Scholar
  47. 47.
    Flory JD, Manuck SB, Ferrell Re et al (2000) Memory performance and the apolipoprotein E polymorphism in a community sample of middle-aged adults. Am J Med Genet 96:707–711PubMedCrossRefGoogle Scholar
  48. 48.
    Nilsson LG, Nyberg L, Backman L (2002) Genetic variation in memory functioning. Neurosci Biobehav Review 26:841–848CrossRefGoogle Scholar
  49. 49.
    Caselli RJ, Osborne D, Reiman EM et al (2001) Preclinical cognitive decline in late middle-aged asymptomatic apolipoprotein E-e4/4 homozygotes: a replication study. J Neurol Sci 189:93–99PubMedCrossRefGoogle Scholar
  50. 50.
    Smith GE, Bohac DL, Waring SC et al (1998) Apolipoprotein E genotype influences cognitive phenotype in patients with Alzheimer’s disease but not in healthy control subjects. Neurology 50:355–362PubMedGoogle Scholar
  51. 51.
    Hyman BT, Gomez-Isla T, Briggs M et al (1996) Influence of APOE genotype on developing cognitive impairment in the general population. Ann Neurol 40:55–66PubMedCrossRefGoogle Scholar
  52. 52.
    Greenberg SM, Hyman BT (1997) Cerebral amyloid and Apolipoprotein E: bad news for the good allele? Ann Neurol 41:716–721CrossRefGoogle Scholar
  53. 53.
    Sugihara S, Ogawa A, Nakazaro Y et al (1995) Cerebral B amyloid deposition in patients with malignant neoplasms: its prevalence with aging and effects of radiation therapy on vascular amyloid. Acta Neuropathol 90:135–141PubMedGoogle Scholar
  54. 54.
    Behin A, Delattre JY (2003) Neurologic sequelae of radiotherapy of the nervous system. In: Schiff D, Wen PY (eds) Cancer neurology in clinical practice. Humana Press, Totowa, pp 173–192Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2006

Authors and Affiliations

  • Denise D. Correa
    • 1
    • 2
    Email author
  • Lisa M. DeAngelis
    • 1
    • 2
  • Weiji Shi
    • 3
  • Howard T. Thaler
    • 3
  • Michael Lin
    • 2
  • Lauren E. Abrey
    • 1
    • 2
  1. 1.Department of NeurologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.Department of Neurology and NeuroscienceWeill Medical College of Cornell UniversityNew YorkUSA
  3. 3.Departments of Epidemiology and BiostatisticsMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations